Vyvanse vs Concerta for adults: amphetamine or methylphenidate, once a day

Vyvanse and Concerta are two of the most widely prescribed long-acting ADHD medicines for adults, and they come from different stimulant families. Vyvanse (lisdexamfetamine) is an amphetamine prodrug. Concerta is extended-release methylphenidate. Both are taken once in the morning, both are FDA-approved for ADHD in adults, and both are Schedule II controlled substances with the same boxed warning. This page compares them using the FDA labels and published adult research, as of October 2026.

Side by side

How each one stretches across the day

Vyvanse gets its long action from chemistry. Its label states that lisdexamfetamine "is a prodrug of dextroamphetamine," so the capsule contains a compound that must be converted in the body before it works. Because the effect does not depend on a tablet coating or beads, the label allows the capsule to be opened and mixed into food or a drink.

Concerta gets its long action from engineering. Its label describes an initial rise in blood levels at about one hour, a gradual climb over the next 5 to 9 hours, and then a slow decline. The tablet shell does not dissolve, so it must be swallowed whole, and the empty shell may appear in the stool.

What the research says in adults

A large head-to-head trial of Vyvanse against Concerta in adults was not found for this guide. The evidence is indirect.

• Family-level comparisons. The 2018 Lancet Psychiatry network meta-analysis (Cortese and colleagues) grouped "amphetamines (including lisdexamfetamine)" and "methylphenidate." In adults, amphetamines showed a larger short-term reduction in clinician-rated symptoms than methylphenidate. Both were less well tolerated than placebo in adults.
• Guidelines. The UK NICE guideline names lisdexamfetamine and methylphenidate as the two first-line medications for adults and recommends switching to the other if a six-week trial of one at an adequate dose does not help enough. That recommendation itself reflects the experience that response differs from person to person.
• Long-term data. The 2018 analysis found too few trials at 26 and 52 weeks to compare medicines over longer periods, and a 2025 analysis (Ostinelli and colleagues) noted that longer-term evidence remains underinvestigated.

None of this shows that one is the right first choice for every adult. Factors like other health conditions, swallowing, sleep, other medicines and past response often decide it. How doctors choose an ADHD medication walks through those factors.

Practical differences

• Swallowing. Vyvanse capsules can be opened, and a chewable tablet exists. Concerta must be swallowed whole.
• Age wording. Concerta's label covers patients up to 65. The Vyvanse ADHD indication has no upper age limit.
• Eye and digestive warnings. Concerta, like other methylphenidate products, lists acute angle-closure glaucoma and increased eye pressure, and adds a warning about blockage in people with a severely narrowed digestive tract.
• Binge eating disorder. Vyvanse is the only one of the two approved for moderate to severe binge eating disorder in adults. The label says it is not indicated for weight loss.
• Interactions. Vyvanse's label notes that urinary alkalinizing agents such as sodium bicarbonate raise amphetamine levels and acidifying agents such as ascorbic acid lower them. Both are contraindicated with MAOIs.
• Supply. Both are on the FDA's current shortage list as of October 19, 2026. See what to do when your pharmacy is out of stock.

For more on each, see Vyvanse for adults and Concerta for adults. Heart and blood pressure questions, which apply to both, are covered in ADHD medication, heart health and blood pressure.

New York and New Jersey rules that apply to both

Both medications on this page are Schedule II controlled substances, so the same prescription rules apply to either one. In New York, a Schedule II prescription cannot be refilled; when more medication is needed, the prescriber issues a new prescription (10 NYCRR 80.67). New Jersey's controlled dangerous substance rules also bar refills of Schedule II prescriptions (N.J.A.C. 13:45H-7.9). Supply limits, the 30-day window to fill, electronic prescribing and the monitoring-program checks are covered in New York's rules for ADHD stimulant prescriptions and New Jersey's rules for ADHD stimulant prescriptions. Switching from one stimulant to another does not change any of these rules.

Questions worth asking

• Have I taken a medicine from either family before, and how did it go?
• Can I swallow a tablet whole every day, or would a capsule I can open be easier?
• Do I have glaucoma, digestive narrowing, heart disease or high blood pressure?
• What is our backup plan if the pharmacy is out of stock?
• How will we decide whether to switch families if the first one does not help enough?

Talking it through with a prescriber

Dr. Shershow is a psychiatrist who focuses on adult ADHD and is licensed in New York and New Jersey. After an adult ADHD evaluation, he discusses the treatment options that fit, including medication when it is appropriate, and follows up over time. The comparison above is general information from FDA labels and published research. It is not advice to start, stop or switch any medication, and neither drug is the right choice for everyone.